388 related articles for article (PubMed ID: 11698275)
1. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).
Bacigalupo A; Lamparelli T; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Barbanti M; Sacchi N; Van Lint MT; Bosi A
Blood; 2001 Nov; 98(10):2942-7. PubMed ID: 11698275
[TBL] [Abstract][Full Text] [Related]
2. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
[TBL] [Abstract][Full Text] [Related]
3. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
4. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
5. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
6. Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantation.
Atta EH; de Oliveira DC; Bouzas LF; Nucci M; Abdelhay E
PLoS One; 2014; 9(9):e107155. PubMed ID: 25188326
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants.
Bacigalupo A; Lamparelli T; Gualandi F; Bregante S; Raiola AM; Di Grazia C; Dominietto A; Bruno B; Galbusera V; Frassoni F; Podesta M; Tedone E; Occhini D; Van Lint MT
Biol Blood Marrow Transplant; 2002; 8(12):656-61. PubMed ID: 12523577
[TBL] [Abstract][Full Text] [Related]
8. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
9. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
[TBL] [Abstract][Full Text] [Related]
10. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin.
Finke J; Schmoor C; Lang H; Potthoff K; Bertz H
J Clin Oncol; 2003 Feb; 21(3):506-13. PubMed ID: 12560442
[TBL] [Abstract][Full Text] [Related]
11. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.
Van Lint MT; Uderzo C; Locasciulli A; Majolino I; Scimé R; Locatelli F; Giorgiani G; Arcese W; Iori AP; Falda M; Bosi A; Miniero R; Alessandrino P; Dini G; Rotoli B; Bacigalupo A
Blood; 1998 Oct; 92(7):2288-93. PubMed ID: 9746766
[TBL] [Abstract][Full Text] [Related]
12. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
[TBL] [Abstract][Full Text] [Related]
13. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
15. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Mohty M; Bay JO; Faucher C; Choufi B; Bilger K; Tournilhac O; Vey N; Stoppa AM; Coso D; Chabannon C; Viens P; Maraninchi D; Blaise D
Blood; 2003 Jul; 102(2):470-6. PubMed ID: 12649133
[TBL] [Abstract][Full Text] [Related]
16. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.
Socié G; Schmoor C; Bethge WA; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Finke J;
Blood; 2011 Jun; 117(23):6375-82. PubMed ID: 21467544
[TBL] [Abstract][Full Text] [Related]
17. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
[TBL] [Abstract][Full Text] [Related]
18. Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin.
Hatanaka K; Fuji S; Ikegame K; Kato R; Wake A; Hidaka M; Ito T; Inoue M; Nagatoshi Y; Takami A; Uike N; Sakamaki H; Yabe H; Morishima Y; Suzuki R; Atsuta Y; Fukuda T
Int J Hematol; 2012 Dec; 96(6):773-80. PubMed ID: 23132596
[TBL] [Abstract][Full Text] [Related]
19. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO
Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
[TBL] [Abstract][Full Text] [Related]
20. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1422-30. PubMed ID: 19822302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
